Despite Late-Stage Hemophilia Win, Sangamo Remains in Do-or-Die Situation

[cafead]

via Sangamo and Pfizer’s hemophilia A gene therapy candidate scored a Phase III victory last week. However, with the genomic medicine company soon to run out of cash, Sangamo’s short-term prospects look bleak but not unsalvageable, analysts say.

article source